Neural network measures MS disease progression
The percentage of brain volume is an important marker of disease progression in multiple sclerosis. Researchers have developed a prototype neural network-based quantification system to measure this important benchmark by computer-assisted segmentation of multispectral MR imaging data.
The percentage of brain volume is an important marker of disease progression in multiple sclerosis. Researchers have developed a prototype neural network-based quantification system to measure this important benchmark by computer-assisted segmentation of multispectral MR imaging data.
Dr. Axel Wismueller of Ludwig Maximilians University in Munich performed MR exams in six women with relapsing-remitting MS. The neural network computed the percentage of brain volume by automatic cerebrospinal fluid segmentation. The voxel-specific gray-level intensity spectrum forms a seven-dimensional feature vector, which is classified by the neural network as either belonging to CSF or not. Findings were reported at the 2005 European Congress of Radiology.
The neural network-based computation significantly outperformed the conventional angle-image method. Specifically, the neural network performed better by retrieving only T2-weighted and perfusion/diffusion-weighted signals, thereby avoiding misclassifications in white matter lesions that are difficult to distinguish from CSF.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
